Subpopulations

(absolute numbers)

Patients with RMS (favorable localization of the primary tumor)

Control group

Р

CD3+ HLADR+

5.5 ± 1.8 (n = 3)

2.5 ± 0.6 (n = 11)

0.047

CD8+ HLADR+

4.4 ± 1.6 (n = 2)

1.8 ± 0.4 (n = 10)

0.048